Early treatment with fluvoxamine, inhaled budesonide reduces severe COVID-19 risk

Early treatment with oral fluvoxamine plus inhaled budesonide reduced the incidence of progression to severe disease among high-risk outpatients with COVID-19, according to research published in Annals of Internal Medicine.
There is an “urgent need” for effective, accessible treatments for early SARS-CoV-2 infection, particularly for patients who do not have access to effective monoclonal antibodies or oral protease inhibitors, Gilmar Reis, MD, PhD, an associate professor of health research at McMaster University in Canada and director of the cardiovascular research unit at

Early treatment with oral fluvoxamine plus inhaled budesonide reduced the incidence of progression to severe disease among high-risk outpatients with COVID-19, according to research published in Annals of Internal Medicine.
There is an “urgent need” for effective, accessible treatments for early SARS-CoV-2 infection, particularly for patients who do not have access to effective monoclonal antibodies or oral protease inhibitors, Gilmar Reis, MD, PhD, an associate professor of health research at McMaster University in Canada and director of the cardiovascular research unit at